Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.4% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price was down 2.4% during mid-day trading on Tuesday . The company traded as low as $7.50 and last traded at $7.76. Approximately 8,984,496 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 15,902,586 shares. The stock had previously closed at $7.95.

Analysts Set New Price Targets

RXRX has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.75.

Recursion Pharmaceuticals Price Performance

The stock has a market capitalization of $2.84 billion, a price-to-earnings ratio of -4.75 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $6.91 and its 200 day moving average is $7.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.43) earnings per share. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,341 shares of company stock worth $393,490. Insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new position in Recursion Pharmaceuticals during the third quarter worth about $25,000. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. KBC Group NV lifted its holdings in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after buying an additional 3,377 shares during the period. Finally, Amalgamated Bank boosted its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.